Research programme: haemoglobin hyperpolymers - Sangui BioTech

Drug Profile

Research programme: haemoglobin hyperpolymers - Sangui BioTech

Alternative Names: SBT-102

Latest Information Update: 08 Apr 2015

Price : $50

At a glance

  • Originator Sangui BioTech International
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory distress syndrome; Septic shock

Most Recent Events

  • 24 Sep 2014 Sangui BioTech has patent protection for Artificial oxygen carriers in USA, Germany, France, Great Britain, Ita­ly and Spain (Sangui BioTech, From 10-K, September 2014)
  • 01 Jun 2014 Preclinical trials in Respiratory distress syndrome in USA (Intraperitonial) (Sangui BioTech, Form 10-K, September 2014)
  • 01 Jun 2014 Preclinical trials in Septic shock in USA (Intraperitonial) (Sangui BioTech, Form 10-K, September 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top